# Enalapril

Drug · id `cardio:enalapril` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Vasotec; Enalapril maleate

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

Enalapril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for VASOTEC tablets (enalapril maleate), lists three uses: treating high blood pressure, treating symptomatic congestive heart failure (usually together with diuretics and digitalis), and slowing the development of overt heart failure in clinically stable people who have no symptoms but have a reduced left ventricular ejection fraction (35 percent or less). Vasotec is the brand name on the label read.

## Technical summary

RxNorm ingredient 3827; UNII 9O25354EPJ. The label names the substance as enalapril maleate, so UNII 9O25354EPJ is the UNII of the maleate salt and is a broad match. MeSH descriptor D004656 is Enalapril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Bausch Health US LLC label for VASOTEC (enalapril maleate) tablets, application NDA018998, effective 2026-01-23 in openFDA; Drugs@FDA lists the application's sponsor as BAUSCH. Other enalapril labels, including the Epaned oral solution label, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients for whom the US label of enalapril (Vasotec) lists an indication: hypertension, symptomatic congestive heart failure, asymptomatic left ventricular dysfunction with ejection fraction 35 percent or less

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of VASOTEC (enalapril maleate) tablets, in the Bausch Health US LLC version dated 2026-01-23 in openFDA, lists the medicine for the treatment of hypertension; for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis; and, in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction 35 percent or less), to decrease the rate of development of overt heart failure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for VASOTEC (enalapril maleate) tablets, Bausch Health US LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 39631f1f-5d19-43c1-b504-bf56d991ed97 (manufacturer Bausch Health US LLC, application NDA018998), returned on 2026-11-09. The label text is dated 2026-01-23 (effective\_time). Other openFDA records of enalapril labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2239631f1f-5d19-43c1-b504-bf56d991ed97%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], INDICATIONS AND USAGE. Retrieved 2026-11-09T13:18:20Z. Source state: Current. Version fingerprint: 5f863c2bf22396afec6b5c4ca54d79c10d17deea45b25bc7f69704b4ea0109a8.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for VASOTEC (enalapril maleate) tablets, Bausch Health US LLC label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id 39631f1f-5d19-43c1-b504-bf56d991ed97 (manufacturer Bausch Health US LLC, application NDA018998), returned on 2026-11-09. The label text is dated 2026-01-23 (effective\_time). Other openFDA records of enalapril labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2239631f1f-5d19-43c1-b504-bf56d991ed97%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:18:20Z. Source state: Current. Version fingerprint: 5f863c2bf22396afec6b5c4ca54d79c10d17deea45b25bc7f69704b4ea0109a8.
     How it applies: Effective date of the label text read, 20260123.
  3. Background: openFDA Drugs@FDA record for application NDA018998 (VASOTEC, sponsor BAUSCH): product and sponsor (Regulator, edition The openFDA Drugs@FDA record for application NDA018998, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018998%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-11-09T13:20:25Z. Source state: Current. Version fingerprint: 416a5458130c571132ec7563ce9664a1d19380b14779e933909278478bb7dad2.
     How it applies: Drugs@FDA product listing for application NDA018998, which confirms the product the label belongs to.

## Connected pages

- Enalapril is an ACE inhibitor (FDA established pharmacologic class in RxClass): ACE inhibitors (`cardio:ace-inhibitors`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-enalapril-label-indications` and its context]
- FDA label lists symptomatic congestive heart failure, and slowing the development of overt heart failure in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction 35 percent or less), as indications: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-enalapril-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- Investigated in: PARADIGM-HF (`cardio:paradigm-hf`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 6 registry products
- 14 registry trials

## Provenance

Content hash: b560f1dde21772e71b0f6957bea5d4e40bb8f477be23a6a624d2f814084b34b8
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
